Researchers are excited about new treatments for hepatitis

March 1996

Researchers are excited about new treatments for hepatitis...especially the chronic, active forms of hepatitis B and C.

Antivirals are being tried...ribavirin for chronic hepatitis C and the new HIV drug, lamivudine (3TC), for chronic hepatitis B.

But no antivirals are approved for hepatitis...because their clinical benefit hasn't been shown. The ribavirin being studied for hepatitis is an ORAL form...not the aerosol version used for RSV.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote